• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

青春期女性闭经作为乌帕替尼治疗特应性皮炎的罕见不良事件

Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis.

作者信息

Teng Yan, Tang Yi, Fan Yibin, Tao Xiaohua, Ding Yang

机构信息

Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, People's Republic of China.

出版信息

Patient Prefer Adherence. 2024 Nov 14;18:2307-2310. doi: 10.2147/PPA.S484647. eCollection 2024.

DOI:10.2147/PPA.S484647
PMID:39564523
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11573685/
Abstract

Atopic dermatitis (AD) is a common chronic inflammatory cutaneous disease. Upadacitinib, a selective JAK-1 inhibitor, has been approved as a systemic medication for moderate-to-severe AD in patients aged ≥12 years. Although previous studies have examined the safety profile of upadacitinib, this is the first report to describe a potential association between amenorrhea and upadacitinib or other JAK inhibitors. Herein, we report a rare adverse event of amenorrhea in an adolescent female patient who was treated with upadacitinib for AD. This case report expands the range of adverse events potentially associated with upadacitinib therapy.

摘要

特应性皮炎（AD）是一种常见的慢性炎症性皮肤病。乌帕替尼是一种选择性JAK-1抑制剂，已被批准作为≥12岁中度至重度AD患者的全身用药。尽管先前的研究已经考察了乌帕替尼的安全性，但这是第一份描述闭经与乌帕替尼或其他JAK抑制剂之间潜在关联的报告。在此，我们报告一名青少年女性特应性皮炎患者在接受乌帕替尼治疗时出现闭经这一罕见不良事件。本病例报告扩展了与乌帕替尼治疗可能相关的不良事件范围。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9440/11573685/1bfa8de278a7/PPA-18-2307-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9440/11573685/1bfa8de278a7/PPA-18-2307-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9440/11573685/1bfa8de278a7/PPA-18-2307-g0001.jpg

相似文献

1
Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis.青春期女性闭经作为乌帕替尼治疗特应性皮炎的罕见不良事件
Patient Prefer Adherence. 2024 Nov 14;18:2307-2310. doi: 10.2147/PPA.S484647. eCollection 2024.
2
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.度普利尤单抗联合局部皮质类固醇治疗青少年和成人中重度特应性皮炎（AD Up）的安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的结果。
Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.
3
A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.一项在日本开展的3期随机、多中心、双盲研究，旨在评估乌帕替尼联合外用皮质类固醇激素治疗中度至重度特应性皮炎青少年及成年患者的安全性（Rising Up）：一项24周中期分析。
JAAD Int. 2021 Dec 20;6:27-36. doi: 10.1016/j.jdin.2021.11.001. eCollection 2022 Mar.
4
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.每日一次乌帕替尼对比安慰剂治疗中重度特应性皮炎青少年和成人患者（Measure Up1 和 Measure Up2）：两项复制性、双盲、随机对照 3 期临床试验结果。
Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21.
5
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.乌帕替尼治疗中重度特应性皮炎的安全性：3 期研究的综合分析。
J Allergy Clin Immunol. 2023 Jan;151(1):172-181. doi: 10.1016/j.jaci.2022.09.023. Epub 2022 Oct 1.
6
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).度普利尤单抗治疗成人和青少年中重度特应性皮炎的疗效和生活质量：两项 III 期随机临床试验（Measure Up 1 和 Measure Up 2）的 52 周结果。
Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25.
7
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.乌帕替尼治疗中重度特应性皮炎青少年患者的疗效和安全性：Measure Up 1、Measure Up 2 和 AD Up 随机临床试验分析。
JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391.
8
Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.度普利尤单抗治疗青少年及成人中重度特应性皮炎的真实世界疗效及耐受性。
Adv Ther. 2023 May;40(5):2509-2514. doi: 10.1007/s12325-023-02490-5. Epub 2023 Mar 21.
9
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.乌帕替尼加局部皮质类固醇治疗特应性皮炎：第 52 周 AD Up 研究结果。
J Allergy Clin Immunol. 2022 Mar;149(3):977-987.e14. doi: 10.1016/j.jaci.2021.07.036. Epub 2021 Aug 14.
10
Efficacy and Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Meta-Analysis.乌帕替尼治疗中度至重度特应性皮炎的疗效和安全性：一项荟萃分析。
Cureus. 2024 Jul 13;16(7):e64488. doi: 10.7759/cureus.64488. eCollection 2024 Jul.

本文引用的文献

1
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.托法替尼治疗幼年特发性关节炎患者的安全性和疗效：一项开放性、长期扩展研究的初步结果。
Ann Rheum Dis. 2024 Oct 21;83(11):1561-1571. doi: 10.1136/ard-2023-225094.
2
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study.乌帕替尼治疗中重度特应性皮炎日本患者的长期疗效和安全性：一项真实世界临床研究。
J Dermatolog Treat. 2024 Dec;35(1):2344591. doi: 10.1080/09546634.2024.2344591. Epub 2024 Apr 23.
3
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan.
在中度至重度特应性皮炎患者中，从巴瑞替尼4毫克转换为乌帕替尼30毫克的有效性：日本的一项真实世界临床实践。
J Dermatolog Treat. 2023 Dec;34(1):2276043. doi: 10.1080/09546634.2023.2276043. Epub 2023 Dec 10.
4
Current and Emerging Therapies for Atopic Dermatitis in the Elderly.老年人特应性皮炎的现有和新兴疗法。
Clin Interv Aging. 2023 Oct 2;18:1641-1652. doi: 10.2147/CIA.S426044. eCollection 2023.
5
Upadacitinib for moderate to severe atopic dermatitis.巴瑞替尼治疗中重度特应性皮炎。
Immunotherapy. 2023 Aug;15(11):799-808. doi: 10.2217/imt-2023-0037. Epub 2023 May 17.
6
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.巴瑞替尼治疗特应性皮炎 1.6 年及长达 3.9 年的安全性：八项临床试验的更新综合分析。
J Dermatolog Treat. 2023 Dec;34(1):2161812. doi: 10.1080/09546634.2022.2161812.
7
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.度普利尤单抗治疗中重度特应性皮炎的疗效和安全性：来自两项随机临床试验 MEASURE UP 1 和 MEASURE UP 2 的随访数据分析。
JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.
8
How does atopic dermatitis in childhood and adolescence affect educational success?儿童和青少年特应性皮炎如何影响学业成就？
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1746. doi: 10.1111/jdv.17518.
9
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.乌帕替尼对比度普利尤单抗治疗成人中重度特应性皮炎的疗效和安全性：一项随机临床试验。
JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023.
10
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.每日一次乌帕替尼对比安慰剂治疗中重度特应性皮炎青少年和成人患者（Measure Up1 和 Measure Up2）：两项复制性、双盲、随机对照 3 期临床试验结果。
Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21.